New growth phase for Eindhoven mold specialist
Investment company BC Partners acquires stake in IGS GeboJagema.
Published on June 7, 2025
Team IO+ selects and features the most important news stories on innovation and technology, carefully curated by our editors.
Investment company BC Partners has acquired a majority stake in IGS GeboJagema, a manufacturer of high-precision molds for the medical industry. The Eindhoven-based company will continue to be supported by co-investor Smile Invest and its own management team, which will retain a minority stake.
Rabo Private Equity, which was also a shareholder until now, is withdrawing completely. No amounts have been disclosed for this deal.
IGS is an international leader in the production of molds for medical applications, including injection aids, contact lenses, and diagnostic equipment.
From its headquarters in Eindhoven, a research facility at Brainport Industries Campus, and a branch in the US state of Georgia, the company serves major pharmaceutical and healthcare customers worldwide. With a team of 174 employees and a strong focus on precision and repeatability, IGS plays a key role in the production of critical medical devices.
According to CEO Herman Rusch, BC Partners' entry marks “an exciting new chapter” in the development of IGS. “Their investment is a recognition of our team's expertise and dedication. We want to further expand our market position, including in the fast-growing GLP-1 market and other segments with high precision requirements.”
BC Partners brings extensive experience in healthcare and specialized manufacturing. Previous investments in companies such as Synthon, IMA, and Pharmathen demonstrate their expertise in scaling up and internationalizing innovative companies. “We look forward to working with Smile and the IGS team to capitalize on new growth opportunities,” said Matthew Evans, managing director at BC Partners.
Smile Invest will remain a shareholder. Partner Bart Cauberghe calls the addition of BC Partners “a logical next step in IGS's growth journey.” The deal is subject to approval by the works council and relevant regulatory authorities.
With the new ownership structure, IGS is committed to accelerated international expansion, strategic acquisitions, and expansion into new markets within the healthcare sector.
Herman Rusch and Erik Veurink at BIC